Welcome to our dedicated page for Kineta news (Ticker: KA), a resource for investors and traders seeking the latest updates and insights on Kineta stock.
Kineta Inc. news covered a clinical-stage biotechnology company developing immunotherapies in oncology for cancer immune resistance. Recurring updates centered on KVA12123, a VISTA blocking monoclonal antibody evaluated in the VISTA-101 Phase 1/2 trial for advanced solid tumors, including monotherapy cohorts and combination cohorts with KEYTRUDA (pembrolizumab).
Company announcements also addressed clinical data presentations, trial enrollment changes, the TuHURA exclusivity and right-of-first-offer arrangement for KVA12123, corporate restructuring, strategic-alternatives activity, and Kineta's transition from Nasdaq to OTC Pink trading under KANT before its later merger into Kineta, LLC.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.